Found 185 clinical trials
Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer
This phase II trial studies how well alpelisib works in treating participants with human papillomavirus(HPV)-associated stage I-IVA head and neck cancer that can be removed by surgery. Alpelisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- 0 views
- 27 Jan, 2021
- 1 location
Effects of Curcumin Supplementation in Patients With Chronic Kidney Disease on Peritoneal Dialysis
The objective of this study is to assess whether supplementation with curcumin could modulate the intestinal microbiota, reducing levels of inflammatory markers of oxidative stress, uremic toxins and inflammasome, in patients with chronic kidney disease in peritoneal dialysis.
- 0 views
- 26 Jan, 2021
- 1 location
Microbiome in Cancer Patients With High Dose Chemotherapy With Stem Cell Transplantation
Numerous in vitro and animal studies as well as growing number of clinical studies support the important role of microbiome in carcinogenesis and cancer treatment. Detection of changes in patients microbiome following hematopoietic cell transplantation/CAR-T cell therapy and correlations with adverse transplant outcomes, mainly infectious complications, acute and chronic GvHD, …
- 0 views
- 13 Mar, 2021
- 1 location
Papaverine and Stereotactic Body Radiotherapy (SBRT) for Non Small Cell Lung Cancer (NSCLC) or Lung Metastases
This phase I trial studies the side effects and how well papaverine hydrochloride and stereotactic radiation therapy body (SBRT) work in treating patients with non-small cell lung cancer. Papaverine hydrochloride may help radiation therapy work better by making tumor cells more sensitive to the radiation therapy. Stereotactic body radiation therapy …
- 0 views
- 15 Feb, 2021
- 1 location
Ellagic Acid Urolithin and Colonic Microbial Communities Affected by Walnut Consumption
Briefly, this is a 28-day dietary intervention study participants will be asked to eat 2 ounces (52 grams) of walnuts every day for 3 weeks, and at the end of the study period they will come in for a colonoscopy. Participants will first start a 1-week run-in period where they …
- 0 views
- 25 Mar, 2021
- 1 location
Abemaciclib in Treating Patients With Surgically Resectable Chemotherapy Resistant Triple Negative Breast Cancer
This phase II trial studies how well abemaciclib works in treating patients with triple negative breast cancer that can be removed by surgery (resectable) and does not respond to treatment with chemotherapy. Abemaciclib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
- 6 views
- 19 Jun, 2021
- 6 locations
Circulating Tumor DNA in Soft Tissue Sarcoma
This research study will collect blood and tumor tissue samples from patients with soft tissue sarcoma to look at circulating tumor deoxyribonucleic acid (DNA). When tumor cells are damaged or die, DNA from the tumor cells are released into the blood stream as the cells break down. This is called …
- 3 views
- 22 Apr, 2021
- 1 location
MRD-guided Treatment in NPM1mut AML Patients
Evaluation the safety and efficacy of Pembrolizumab (PEM) when administered in combination with standard Azacitidine (AZA) in nucleophosmin (NPM1) mutated AML patients with molecular relapse defined by the presence of measurable residual disease (MRD).
- 2 views
- 24 Jan, 2021
- 17 locations
Daratumumab Bortezomib and Dexamethasone Followed by Daratumumab Ixazomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
This phase II trial studies how well daratumumab, bortezomib, and dexamethasone followed by daratumumab, ixazomib, and dexamethasone in treating patients with multiple myeloma that has come back (relapsed) or does not response to treatment (refractory). Immunotherapy with monoclonal antibodies, such as daratumumab, may help the body's immune system attack the …
- 3 views
- 18 Apr, 2021
- 1 location
Talazoparib in Treating Patients With Recurrent Refractory Advanced or Metastatic Cancers and Alterations in the BRCA Genes
This phase II trial studies how well talazoparib works in treating patients with cancers that have returned after a period of improvement, do not respond to treatment, or have spread to other parts of the body, and have alterations in the breast cancer, early onset (BRCA) genes. Talazoparib may cause …
- 10 views
- 15 Jun, 2021
- 2 locations